Quantitative imaging of a therapeutic peptide in biological tissue sections by MALDI MS

Bioanalysis

Volumn 5, Issue 5, 2013, Pages 603-612

  Takai, Nozomi ^a   Tanaka, Yukari ^a   Watanabe, Ayahisa ^a   Saji, Hideo ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENTISIC ACID; OCTREOTIDE; PEPTIDE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STRUCTURE; DRUG TISSUE LEVEL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION IMAGING MASS SPECTROMETRY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GELATIN; GENTISATES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; OCTREOTIDE; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84874167570     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.13     Document Type: Article

References (48)

1. Kafka AP, Kleffmann T, Rades T, McDowell A. The application of MALDI TOF MS in biopharmaceutical research. Int. J. Pharm. 417(1-2), 70-82 (2011).
2. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11(7), 527-540 (2012).
3. Monro AM. Are routine tissue distribution studies justifiable for approval of human drugs? Drug Metab. Dispos. 22(3), 341-342 (1994). (Pubitemid 24158529)
4. Campbell DB. Are we doing too many animal biodisposition investigations before phase I studies in man? A re-evaluation of the timing and extent of ADME studies. Eur. J. Drug Metab. Pharmacokinet. 19(3), 283-293 (1994). (Pubitemid 24331199)
5. Mizojiri K, Shindo H, Ohno Y. The possibility of predicting tissue accumulation after repeated dosing using a single-dose tissue distribution study. J. Toxicol. Sci. 21(5), 523-527 (1996). (Pubitemid 27044252)
6. Steinke W, Archimbaud Y, Becka M et al. Quantitative distribution studies in animals: Cross-validation of radioluminography versus liquid-scintillation measurement. Regul. Toxicol. Pharmacol. 31(2 Pt 2), S33-S43 (2000). (Pubitemid 30314339)
7. D'Argy R, Sundwall A. Quantitative whole-body radioluminography-future strategy for balance and tissue distribution studies. Regul. Toxicol. Pharmacol. 31(2 Pt 2), S57-S62 (2000). (Pubitemid 30314342)
8. Solon EG, Kraus L. Quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. J. Pharmacol. Toxicol. Methods 46(2), 73-81 (2001). (Pubitemid 34680996)
9. Inazawa K, Koike M, Yamaguchi T. Study on the practical use of quantitative whole-body auto-radioluminography. Exp. Mol. Pathol. 76(2), 153-165 (2004). (Pubitemid 38316930)
10. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 69(23), 4751-4760 (1997).
11. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA, Caprioli RM. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 38(10), 1081-1092 (2003). (Pubitemid 37407703)
12. Marshall P, Toteu-Djomte V, Bareille P et al. Correlation of skin blanching and percutaneous absorption for glucocorticoid receptor agonists by matrix-assisted laser desorption ionization mass spectrometry imaging and liquid extraction surface analysis with nanoelectrospray ionization mass spectrometry. Anal. Chem. 82(18), 7787-7794 (2010).
13. Zaima N, Sasaki T, Tanaka H et al. Imaging mass spectrometry-based histopathologic examination of atherosclerotic lesions. Atherosclerosis 217(2), 427-432 (2011).
14. Clemis EJ, Smith DS, Camenzind AG, Danell RM, Parker CE, Borchers CH. Quantitation of spatially-localized proteins in tissue samples using MALDI-MRM imaging. Anal. Chem. 84(8), 3514-3522 (2012).
15. Khatib-Shahidi S, Andersson M, Herman JL, Gillespie TA, Caprioli RM. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal. Chem. 78(18), 6448-6456 (2006). (Pubitemid 44418954)
16. Atkinson SJ, Loadman PM, Sutton C, Patterson LH, Clench MR. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 21(7), 1271-1276 (2007). (Pubitemid 46509403)
17. Li F, Hsieh Y, Kang L, Sondey C, Lachowicz J, Korfmacher WA. MALDI-tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections. Bioanalysis 1(2), 299-307 (2009).
18. Castellino S, Groseclose MR, Wagner D. MALDI imaging mass spectrometry: Bridging biology and chemistry in drug development. Bioanalysis 3(21), 2427-2441 (2011).
19. Gobey J, Cole M, Janiszewski J et al. Characterization and performance of MALDI on a triple quadrupole mass spectrometer for analysis and quantification of small molecules. Anal. Chem. 77(17), 5643-5654 (2005). (Pubitemid 41266060)
20. Marto JA, White FM, Seldomridge S, Marshall AG. Structural characterization of phospholipids by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 67(21), 3979-3984 (1995).
21. Vaidyanathan S, Gaskell S, Goodacre R. Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid Commun. Mass Spectrom. 20(8), 1192-1198 (2006).
22. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60(20), 2299-2301 (1988).
23. Hillenkamp F, Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol. 193, 280-295 (1990).
24. Stauber J. Quantitation by MS imaging: needs and challenges in pharmaceuticals. Bioanalysis 4(17), 2095-2098 (2012).
25. Reich RF, Cudzilo K, Levisky JA, Yost RA. Quantitative MALDI-MS(n) analysis of cocaine in the autopsied brain of a human cocaine user employing a wide isolation window and internal standards. J. Am. Soc. Mass Spectrom. 21(4), 564-571 (2010).
26. Nilsson A, Fehniger TE, Gustavsson L et al. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS ONE 5(7), e11411 (2010).
27. Shin YG, Dong T, Chou B, Menghrajani K. Determination of loperamide in mdr1a/1b knock-out mouse brain tissue using matrix-assisted laser desorption/ionization mass spectrometry and comparison with quantitative electrospray-triple quadrupole mass spectrometry analysis. Arch. Pharm. Res. 34(11), 1983-1988 (2011).
28. Goodwin RJ, Nilsson A, Borg D et al. Conductive carbon tape used for support and mounting of both whole animal and fragile heat-treated tissue sections for MALDI MS imaging and quantitation. J. Proteomics 75(16), 4912-4920 (2012).
29. Hamm G, Bonnel D, Legouffe R et al. Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor. J. Proteomics 75(16), 4952-4961 (2012).
30. Takai N, Tanaka Y, Inazawa K, Saji H. Quantitative analysis of pharmaceutical drug distribution in multiple organs by imaging mass spectrometry. Rapid Commun. Mass Spectrom. 26(13), 1549-1556 (2012).
31. Stoeckli M, Staab D, Schweitzer A, Gardiner J, Seebach D. Imaging of a beta-peptide distribution in whole-body mice sections by MALDI mass spectrometry. J. Am. Soc. Mass Spectrom. 18(11), 1921-1924 (2007). (Pubitemid 350011150)
32. Tamvakopoulos CS, Colwell LF, Barakat K et al. Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14(19), 1729-1735 (2000).
33. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun. Mass Spectrom. 21(24), 4033-4038 (2007).
34. Kuuranne T, Thomas A, Leinonen A et al. Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing. Rapid Commun. Mass Spectrom. 22(3), 355-362 (2008). (Pubitemid 351212861)
35. Zhang H, Xin B, Caporuscio C, Olah TV. Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies. Rapid Commun. Mass Spectrom. 25(22), 3427-3435 (2011).
36. Li H, Ortiz R, Tran L et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012).
37. Astruc B, Marbach P, Bouterfa H et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol. 45(7), 836-844 (2005). (Pubitemid 40875336)
38. Jiang Y, Wang J, Wang Y et al. Determination of long-acting release octreotide, an octapeptide analog of somatostation, in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21(24), 3982-3986 (2007).
39. Ismaiel OA, Zhangb T, Jenkinsb R, Karnesc HT. Determination of octreotide and assessment of matrix effects in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879(22), 2081-2088 (2011).
40. Lopez LL, Tiller PR, Senko MW, Schwartz JC. Automated strategies for obtaining standardized collisionally induced dissociation spectra on a benchtop ion trap mass spectrometer. Rapid Commun. Mass Spectrom. 13(8), 663-668 (1999). (Pubitemid 29194452)
41. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic somatostatin analog, in rats. Drug Metab. Dispos. 17(6), 699-703 (1989). (Pubitemid 20015116)
42. Krenning EP, Bakker WH, Kooij PPM et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33(5), 652-658 (1992).
43. Lubberink M, Tolmachev V, Widström C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J. Nucl. Med. 43(10), 1391-1397 (2002).
44. Akizawa H, Arano Y, Uezono T et al. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. Bioconjug. Chem. 9(6), 662-670 (1998).
45. Neubert H, Fountain S, King L et al. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD. Bioanalysis 4(21), 2589-2604 (2012).
46. Prideaux B, Dartois V, Staab D et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83(6), 2112-2118 (2011).
47. Seeley EH, Caprioli RM. 3D imaging by mass spectrometry: A new frontier. Anal. Chem. 84(5), 2105-2110 (2012).
48. Trede D, Schiffler S, Becker M et al. Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: Three-dimensional spatial segmentation of mouse kidney. Anal. Chem. 84(14), 6079-6087 (2012).